Isolated Systolic Hypertension Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.
Isolated Systolic Hypertension (ISH)is the dominating hypertensive disease in elderly
people. Much attention has recently been drawn to the strong relationship between the
systolic blood pressure and cardiovascular morbidity.
In previous clinical studies carried out in individuals with normal blood pressure at
baseline SER100 decreased primarily the systolic blood pressure. It is hypothesized that the
effect on systolic blood pressure in hypertensive patients will be larger or equal to the
fall seen in normotensive patients.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00751829 -
Isolated Systolic Hypertension in the Elderly and Very Elderly
|
Phase 3 | |
| Recruiting |
NCT05165251 -
Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension
|
Phase 4 | |
| Terminated |
NCT02088450 -
Systolic Hypertension in Europe Placebo-Controlled Trial
|
Phase 2 | |
| Terminated |
NCT00802893 -
Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction
|
Phase 2 | |
| Completed |
NCT01656408 -
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)
|
Phase 1 |